Matches in Nanopublications for { ?s ?p "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP182003.RAWOOmYLKETWcMQiI6hfo4OgFcqfY8y0LmYPRgafG3MuA130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP182003.RAWOOmYLKETWcMQiI6hfo4OgFcqfY8y0LmYPRgafG3MuA130_provenance.
- NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450213.RAXFysg_Lv-iG5yWclDps3iqpE_Ji6ydDWBzoNx4qdII0130_provenance.
- NP775443.RAG2GQ-nrcVFfdwG-8HWSaI36v2R9t55I6QcdL-M2DIj4130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP775443.RAG2GQ-nrcVFfdwG-8HWSaI36v2R9t55I6QcdL-M2DIj4130_provenance.
- assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP281170.RA_WNv6tSnBtTDAY_jz-smF0w4OC-CoKslR5GJ0yW8QPM130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP281170.RA_WNv6tSnBtTDAY_jz-smF0w4OC-CoKslR5GJ0yW8QPM130_provenance.
- assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578336.RAGEu0ikKZAjFSIA7trOUy-pmlaOxcMtpSe09QDVKkqpY130_provenance.
- NP578340.RALngp7sdYP8W4NXVydyZkFHoqz_aV0TmyGMYbAhJw_v8130_assertion description "[Published FDA-validated HPV testing follow-up data show that the expected rates of CIN III+ and CIN II+ in the HPV-negative ASC-US population are 1.4% and 5%, respectively, with PPV/NPVs (CIN II+) of 20%/99%, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578340.RALngp7sdYP8W4NXVydyZkFHoqz_aV0TmyGMYbAhJw_v8130_provenance.